228 related articles for article (PubMed ID: 20204657)
1. Genetic diversity and medicinal drug response in eye care.
Shastry BS
Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1057-61. PubMed ID: 20204657
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics in ophthalmology.
Shastry BS
Discov Med; 2011 Aug; 12(63):159-67. PubMed ID: 21878193
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and the concept of individualized medicine.
Shastry BS
Pharmacogenomics J; 2006; 6(1):16-21. PubMed ID: 16302022
[TBL] [Abstract][Full Text] [Related]
4. Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care.
Trent RJ; Cheong PL; Chua EW; Kennedy MA
Pathology; 2013 Jun; 45(4):357-70. PubMed ID: 23594690
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacogenomics and the path towards personalized medicine].
Belloso WH; Redal MA
Medicina (B Aires); 2010; 70(3):265-74. PubMed ID: 20529779
[TBL] [Abstract][Full Text] [Related]
6. Human genetic variation and personalized medicine.
Agrawal S; Khan F
Indian J Physiol Pharmacol; 2007; 51(1):7-28. PubMed ID: 17877289
[TBL] [Abstract][Full Text] [Related]
7. (Mis)treating the pharmacogenetic incidentalome.
Kohane IS
Nat Rev Drug Discov; 2012 Feb; 11(2):89-90. PubMed ID: 22293554
[TBL] [Abstract][Full Text] [Related]
8. Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individual's drug responses.
Feng J; Sun J; Wang MZ; Zhang Z; Kim ST; Zhu Y; Sun J; Xu J
Pharmacogenomics; 2010 Oct; 11(10):1403-25. PubMed ID: 21047203
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes.
Alshogran OY
Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1063-1073. PubMed ID: 28871815
[TBL] [Abstract][Full Text] [Related]
10. [State of the art of pharmacogenetic diagnostics in drug therapy].
Kirchheiner J; Seeringer A; Brockmöller J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic Markers of Drug Efficacy and Toxicity.
Yip VL; Hawcutt DB; Pirmohamed M
Clin Pharmacol Ther; 2015 Jul; 98(1):61-70. PubMed ID: 25870137
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.
Abdel-Hamid IA; Andersson KE
Pharmacogenomics; 2009 Oct; 10(10):1625-44. PubMed ID: 19842936
[TBL] [Abstract][Full Text] [Related]
13. [Drug therapy and pharmacogenomics--hopes and facts].
Müller-Zellenberg U; Müller M
Wien Med Wochenschr; 2005 Feb; 155(3-4):45-9. PubMed ID: 15791775
[TBL] [Abstract][Full Text] [Related]
14. Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future.
Haas DM
Obstet Gynecol Surv; 2013 Sep; 68(9):650-4. PubMed ID: 25102121
[TBL] [Abstract][Full Text] [Related]
15. Randomizing 1 eye or 2 eyes: a missed opportunity.
Glassman AR; Melia M
JAMA Ophthalmol; 2015 Jan; 133(1):9-10. PubMed ID: 25256889
[No Abstract] [Full Text] [Related]
16. Can pharmacogenetics help rescue drugs withdrawn from the market?
Shah RR
Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
[TBL] [Abstract][Full Text] [Related]
17. Considerations for randomizing 1 eye or 2 eyes.
Bunce C; Wormald R
JAMA Ophthalmol; 2015 Oct; 133(10):1221. PubMed ID: 26291489
[No Abstract] [Full Text] [Related]
18. Drug delivery to the back of the eye.
Kompella UB
Arch Soc Esp Oftalmol; 2007 Nov; 82(11):667-8; 669-70. PubMed ID: 17979032
[No Abstract] [Full Text] [Related]
19. [Using nanotechnology and nanomaterials in ophthalmology].
Zhdanova OV; Chekman IS; Rykov SO
Lik Sprava; 2010; (5-6):21-30. PubMed ID: 21488365
[TBL] [Abstract][Full Text] [Related]
20. Considerations for randomizing 1 eye or 2 eyes--reply.
Glassman AR; Melia M
JAMA Ophthalmol; 2015 Oct; 133(10):1221. PubMed ID: 26291566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
